Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574827 | 0.90 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL29353376 | 0.90 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL18726574 | 0.90 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL18726765 | 0.84 | HDAC1 (0.40) | HDAC1HDAC2LMNAALDH1A1EHMT2 | |
| SCHEMBL9926762 | 0.83 | HDAC1 (0.39) | HDAC1HDAC2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL18896133 | 0.80 | HDAC1 (0.36) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4348222 | 0.80 | HDAC1 (0.39) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL31005440 | 0.80 | HDAC1 (0.39) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15994284 | 0.78 | HPGD (0.38) | HDAC1HDAC2LMNAALDH1A1 | |
| SCHEMBL18656418 | 0.78 | HDAC1 (0.36) | HDAC1HDAC2LMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107011253-B | Method for producing charged crosslinkers | 伊缪诺金公司 | 2021-01-15 | — | — | CN | disclosed |
| US-10112925-B2 | Methods for the preparation of charged crosslinkers | IMMUNOGEN, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3153504-B1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN INC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20170327486-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9663492-B2 | Methods for the preparation of charged crosslinkers | IMMUNOGEN, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-3153504-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | ImmunoGen, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20160272616-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. | 2016-09-22 | — | — | US | disclosed |
| EP-2648510-B1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9242936-B2 | Methods for the preparation of charged crosslinkers | IMMUNOGEN, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150166482-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8921566-B2 | Methods for the preparation of charged crosslinkers | IMMUNOGEN, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140135502-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8598362-B2 | Methods for the preparation of charged crosslinkers | IMMUNOGEN, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2648510-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | ImmunoGen, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120165537-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012078868-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135502-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | SCLY, STOM, STS | HDAC1 1195/4885HDAC2 1161/4885LMNA 1190/4885 |
| US-10112925-B2 | Methods for the preparation of charged crosslinkers | SCLY, STOM, STS | HDAC1 1195/4885HDAC2 1161/4885LMNA 1190/4885 |
| US-20150166482-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | SCLY, STOM, STS | HDAC1 1195/4885HDAC2 1161/4885LMNA 1190/4885 |
| US-20170327486-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | SCLY, STOM, STS | HDAC1 1195/4885HDAC2 1161/4885LMNA 1190/4885 |
| US-20120165537-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | SCLY, STOM, STS | HDAC1 1195/4885HDAC2 1161/4885LMNA 1190/4885 |
| US-20160272616-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | SCLY, STOM, STS | HDAC1 1195/4885HDAC2 1161/4885LMNA 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.